MML Investors Services LLC Raises Stock Position in Masimo Co. (NASDAQ:MASI)

MML Investors Services LLC lifted its stake in Masimo Co. (NASDAQ:MASI) by 4.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,056 shares of the medical equipment provider’s stock after buying an additional 96 shares during the period. MML Investors Services LLC’s holdings in Masimo were worth $274,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. NBC Securities Inc. lifted its holdings in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the last quarter. HHM Wealth Advisors LLC boosted its holdings in shares of Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the period. Headlands Technologies LLC purchased a new position in shares of Masimo during the second quarter worth approximately $109,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Masimo in the 3rd quarter valued at $118,000. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on MASI shares. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler raised their price target on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. BTIG Research upped their price objective on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company boosted their target price on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $175.67.

Masimo Trading Up 0.5 %

NASDAQ:MASI opened at $168.31 on Thursday. The stock has a market capitalization of $9.01 billion, a price-to-earnings ratio of 116.08 and a beta of 1.01. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $180.97. The stock has a fifty day moving average price of $161.40 and a two-hundred day moving average price of $135.43. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.